Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo controlled diet

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    396 result(s) found for: Placebo controlled diet. Displaying page 1 of 20.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-010116-15 Sponsor Protocol Number: CTU 052 D Start Date*: 2010-05-31
    Sponsor Name:RIEMSER Arzneimittel AG
    Full Title: A multicentre double blind placebo controlled clinical dose- finding study for three doses of Antiadipositum X 112 T® (Cathine-hydrochloride) vs. placebo in 240 patients with a body mass index (BMI...
    Medical condition: diet-related obesity diagnosed by BMI of 30 to 40 kg/m² or diet-related obesity diagnosed by BMI of 27 to 40 kg/m² in patient with coexisting risk factors like hyperlipidaemia, type 2 diabetes mell...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-006180-23 Sponsor Protocol Number: EMD 28162-600 Start Date*: 2007-06-13
    Sponsor Name:Johann Wolfgang Goethe Universität
    Full Title: Einfluss einer Vitamin D-Substitution auf die Insulinresistenz, die Stoffwechseleinstellung und die Lymphozytenfunktion bei Patienten mit Typ 2 Diabetes mellitus
    Medical condition: Non-insulin demanding type 2 diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000254-23 Sponsor Protocol Number: ATL 962/175/CL Start Date*: 2004-11-09
    Sponsor Name:Alizyme Therapeutics Limited
    Full Title: A Phase II Multicentre, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study of ATL 962 to Assess Weight Loss, Safety and Tolerability in Obese Patients with Type II Diabetes being ...
    Medical condition: Treatment of obesity in patients with Type II diabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) SE (Completed) GB (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002481-40 Sponsor Protocol Number: TAK-935-3002 Start Date*: 2021-07-22
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Adult Subj...
    Medical condition: Lennox-Gastaut Syndrome (LGS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10048816 Lennox-Gastaut syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA IT (Completed) FR (Completed) ES (Completed) LV (Completed) GR (Completed) NL (Completed) BE (Completed) PL (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000218-12 Sponsor Protocol Number: C3421005 Start Date*: 2019-08-23
    Sponsor Name:Pfizer Inc.
    Full Title: A 16-WEEK, PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-06882961 ADMINISTRATION IN ADULTS WITH TYPE 2 DIABETES ...
    Medical condition: TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED ON METFORMIN OR DIET AND EXERCISE
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-005076-41 Sponsor Protocol Number: E7001-H002 Start Date*: 2006-11-14
    Sponsor Name:Hvidovre Hospital
    Full Title: Effect of nasal GLP-1 versus placebo on fasting state and postprandial hyperglycaemia in type 2 diabetes. A single centre, prospective, placebo controlled clinical trial evaluating efficacy and sa...
    Medical condition: Diabetes Mellitus type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001731-28 Sponsor Protocol Number: C LF 23-0121 0401 Start Date*: 2004-09-24
    Sponsor Name:FOURNIER Laboratories Ireland
    Full Title: A double-blind, 3-arm study on weight loss with combination of micronised fenofibrate 267 mg and metformin 1700 mg per day compared to metformin 1700 mg and placebo, at 6 months, in obese patients,...
    Medical condition: Obesity
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2021-002480-22 Sponsor Protocol Number: TAK-935-3001 Start Date*: 2021-07-22
    Sponsor Name:Takeda Development Center Americas, Inc
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adul...
    Medical condition: Dravet Syndrome (DS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10073682 Dravet syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA IT (Completed) FR (Completed) ES (Completed) LV (Completed) GR (Completed) NL (Completed) BE (Completed) PL (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-001857-42 Sponsor Protocol Number: EFC14822 Start Date*: 2018-05-09
    Sponsor Name:Hanmi Pharmaceutical Co., Ltd.
    Full Title: A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients with Type 2 Diabetes Mellitus Inadequately Co...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-004226-30 Sponsor Protocol Number: ORA-D-013-2 Start Date*: 2022-03-22
    Sponsor Name:Oramed Ltd.
    Full Title: A Double-Blinded, Placebo-controlled, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects with Type 2 Diabetes Mellitus with Inadequate Glycemic C...
    Medical condition: Type 2 Diabetes Mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-001765-28 Sponsor Protocol Number: BC20750 Start Date*: 2008-10-09
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo in patients with type 2 diabetes me...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-000851-41 Sponsor Protocol Number: DRI5029 Start Date*: 2004-10-04
    Sponsor Name:Sanofi-Synthelabo AB
    Full Title: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter study evaluating the efficacy and safety of four doses of SR147778 in obese patients
    Medical condition: Obesity is becoming a major health problem in western societies. Its prevalence is increasing especially in USA, UK, and Germany. Obesity is responsible for increased morbidity and mortality. The c...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10029883 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002365-19 Sponsor Protocol Number: 2 Start Date*: 2018-08-22
    Sponsor Name:Line Velling Magnussen
    Full Title: Muscle strength and -mass after bariatric surgery - a possible effect of testosterone replacement therapy? Randomized, placebo-controlled and double-blinded study
    Medical condition: General aim To investigate the effect and clinical relevance of testosterone therapy combined with exercise and diet counselling in hypogonadal men undergoing bariatric surgery. Objectives To eval...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001049-25 Sponsor Protocol Number: MK8835-017 Start Date*: 2014-12-16
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Initial Combination of Ertugliflozin (MK-8835/PF-049...
    Medical condition: Treatment of type 2 diabetes mellitus (T2DM) with Inadequate Glycemic Control on Diet and Exercise
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004861 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) CZ (Completed) EE (Completed) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003426-24 Sponsor Protocol Number: CTU079G Start Date*: 2013-02-13
    Sponsor Name:Riemser Pharma GmbH
    Full Title: A multicentre double blind placebo controlled clinical trial to assess efficacy and safety of Alvalin® (cathine hydrochloride) vs. placebo in 265 obese patients/group with a body mass index (BMI) b...
    Medical condition: diet-related obesity diagnosed by BMI of 30 to 45 kg/m²
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002524-27 Sponsor Protocol Number: 14-285 Start Date*: 2014-12-18
    Sponsor Name:University Medical Center Utrecht
    Full Title: A randomized, placebo-controlled, double blind, 4-period, cross-over trial, to study blood pressure lowering effects of losartan, Moxonidine and Low sodium diet in former pre-eclamptic women
    Medical condition: Post Partum Hypertension after preeclamptic pregnancy
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004612-97 Sponsor Protocol Number: CEC-4/CEL Start Date*: 2021-08-12
    Sponsor Name:Dr. Falk Pharma GmbH
    Full Title: A phase IIb, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of ZED1227 in celiac disease subjects experiencing symptoms despite gluten-free diet
    Medical condition: Treatment of celiac disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10007864 Celiac disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) LT (Completed) DE (Completed) NO (Completed) EE (Completed) IE (Completed) AT (Completed) FR (Completed) IT (Completed) SE (Completed) ES (Completed) PL (Completed) BG (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002605-29 Sponsor Protocol Number: NN2211-3659 Start Date*: 2012-05-09
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of liraglutide in combination with metformin versus metformin monotherapy on glycaemic control in children and adolescents with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GR (Completed) GB (Completed) HU (Completed) DE (Not Authorised) BE (Completed) ES (Completed) DK (Completed) NO (Completed) SE (Completed) PL (Completed) AT (Completed) FR (Completed) PT (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002484-25 Sponsor Protocol Number: TAK-935-2002(OV935) Start Date*: 2019-04-29
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH ...
    Medical condition: Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-005622-19 Sponsor Protocol Number: NN9924-4233 Start Date*: 2016-08-18
    Sponsor Name:Novo Nordisk A/S
    Full Title: Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only. A 26-week, randomised, double-blind, placebo-controlled trial
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 08:46:38 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA